At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 52 enrolled
Drug / intervention
Brolucizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
In Brief
A Phase 4 clinical trial evaluating Brolucizumab for Age-related Macular Degeneration. Completed, enrolled 52 participants across 19 sites in 2 countries.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received anti-VEGF (vascular endothelial growth factor) treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesGermany, Switzerland
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartJul 2021
Primary CompletionJan 2024
TodayJul 2026
First PostedDec 22, 2020
Enrollment StartJul 13, 2021
Primary CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.5 years ago
Interventions
Brolucizumabbiological
Intravitreal injection